ストックスクリーナーアプリを入手
29.52
0.77%
0.225
アフターアワーズ：
29.52
前日終値:
$29.30
開ける：
$29.16
24時間の取引高:
1.81M
Relative Volume:
0.75
時価総額：
$4.87B
収益：
$1.51B
当期純損益:
$333.35M
株価収益率:
15.14
EPS:
1.95
ネットキャッシュフロー:
$315.22M
1週間 パフォーマンス:
-0.20%
1か月 パフォーマンス:
-4.99%
6か月 パフォーマンス:
-4.77%
1年 パフォーマンス:
-5.35%
1日の値動き範囲:
$28.97
$29.59
1週間の範囲:
$28.52
$30.10
52週間の値動き範囲:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
ALKS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
29.52 | 4.84B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
118.65 | 53.06B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.18 | 45.11B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.44B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.46 | 32.59B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
489.31 | 20.84B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-11 | 開始されました | Truist | Buy |
| 2025-09-26 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 開始されました | Wells Fargo | Overweight |
| 2025-07-15 | 開始されました | Goldman | Buy |
| 2025-06-17 | アップグレード | UBS | Neutral → Buy |
| 2025-05-28 | 開始されました | Needham | Buy |
| 2025-03-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | アップグレード | UBS | Sell → Neutral |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-11-05 | アップグレード | Stifel | Hold → Buy |
| 2024-06-17 | 開始されました | TD Cowen | Buy |
| 2024-03-19 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-20 | ダウングレード | UBS | Neutral → Sell |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-24 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 開始されました | UBS | Neutral |
| 2022-11-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 開始されました | Piper Sandler | Neutral |
| 2022-04-22 | 再開されました | Goldman | Buy |
| 2022-04-20 | 開始されました | Goldman | Buy |
| 2022-01-27 | アップグレード | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 開始されました | Citigroup | Neutral |
| 2021-10-07 | アップグレード | Jefferies | Hold → Buy |
| 2021-09-02 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-10-15 | アップグレード | Mizuho | Neutral → Buy |
| 2020-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2020-02-14 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-02-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-01-31 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-31 | 開始されました | H.C. Wainwright | Neutral |
| 2019-05-01 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-12-19 | ダウングレード | Goldman | Neutral → Sell |
| 2018-12-14 | 開始されました | Wolfe Research | Underperform |
| 2018-12-13 | ダウングレード | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 開始されました | Piper Jaffray | Neutral |
| 2018-08-07 | 開始されました | Stifel | Hold |
| 2018-06-21 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Alkermes Plc (ALKS) 最新ニュース
(ALKS) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - MSN
Avadel Pharmaceuticals plc and Alkermes plc Announce Proposed Transaction for Acquisition - Quiver Quantitative
Announcement relating to despatch of Rule 15 proposal - The Manila Times
Avadel (NASDAQ: AVDL) sends Rule 15 proposal to equity holders in Alkermes deal - Stock Titan
Capital Fund Management S.A. Makes New $1.14 Million Investment in Alkermes plc $ALKS - MarketBeat
Will Alkermes plc (8AK) stock sustain bullish trend into 2025Fed Meeting & Smart Money Movement Tracker - Newser
ALKS: Elixirxton demonstrates strong efficacy, safety, and dosing flexibility for narcolepsy and hypersomnolence - TradingView
Avadel Pharmaceuticals Announces Mailing of Definitive Proxy Statement Regarding Proposed Acquisition by Alkermes - Quiver Quantitative
Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting - Benzinga
VP Hopkinson Files To Sell 3,748 Of Alkermes PLC [ALKS] - TradingView
Mackenzie Financial Corp Acquires 53,323 Shares of Alkermes plc $ALKS - MarketBeat
Evercore Healthcare Conference - marketscreener.com
How Alkermes plc (8AK) stock valuation compares with sectorQuarterly Profit Report & Daily Profit Focused Screening - Newser
Is Alkermes plc (8AK) stock a safe buy pre earningsMarket Growth Summary & Real-Time Sentiment Analysis - Newser
Insider Selling: Alkermes (NASDAQ:ALKS) EVP Sells 4,000 Shares of Stock - MarketBeat
Regeneron, Tessera to advance gene editing therapy for AATD: Deals Report - biocentury.com
How supply chain issues affect Alkermes plc stockPortfolio Performance Report & Real-Time Stock Movement Alerts - Newser
Is Alkermes plc (8AK) stock among top earnings playsQuarterly Trade Review & Real-Time Volume Surge Alerts - Newser
Insider Sell: Craig Hopkinson Sells 4,000 Shares of Alkermes PLC (ALKS) - GuruFocus
Alkermes plc. Officer Sells 4,000 Shares - TradingView
VP Hopkinson Sells 4,000 ($117.2K) Of Alkermes PLC [ALKS] - TradingView
Avadel Pharmaceuticals plc Announces Scheme Meeting for Alkermes Acquisition Proposal - Quiver Quantitative
Avadel Pharmaceuticals (Nasdaq: AVDL) to hold Scheme and EGM on Alkermes takeover Jan. 12 - Stock Titan
Rhumbline Advisers Purchases 17,660 Shares of Alkermes plc $ALKS - MarketBeat
Legal & General Group Plc Sells 17,227 Shares of Alkermes plc $ALKS - MarketBeat
Loomis Sayles & Co. L P Sells 330,389 Shares of Alkermes plc $ALKS - MarketBeat
JPMorgan Chase & Co. Trims Stock Position in Alkermes plc $ALKS - MarketBeat
Alkermes plc $ALKS Shares Sold by Ensign Peak Advisors Inc - MarketBeat
Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report? - sharewise.com
Avadel (AVDL) Drops 6.7% on Lack of Leads - Finviz
Lundbeck Concedes Avadel Bidding War, But Remains On The Hunt - Citeline News & Insights
Alkermes (ALKS) Expected to Complete Avadel Acquisition in Early 2026 - GuruFocus
How (ALKS) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
American Century Companies Inc. Has $104.63 Million Position in Alkermes plc $ALKS - MarketBeat
Alkermes to Participate in Two Upcoming December 2025 Investor Conferences - BioSpace
Alkermes to Participate in Two Upcoming Investor Conferences - Barchart.com
United StatesGoodwin Advises Avadel Pharmaceuticals On Increased Offer From Alkermes - Mondaq
Magnetar Financial LLC Acquires Shares of 123,678 Alkermes plc $ALKS - MarketBeat
TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment - MSN
How Analysts See the Alkermes Story Changing After Acquisition Moves and New Narcolepsy Data - Yahoo Finance
SG Americas Securities LLC Has $1.74 Million Position in Alkermes plc $ALKS - MarketBeat
Is Alkermes plc (8AK) stock a fit for income portfoliosRecession Risk & Consistent Growth Stock Picks - newser.com
Alkermes stock rating reiterated at Neutral by H.C. Wainwright - Investing.com Australia
ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - Finviz
Alkermes Faces Bidding Battle For Avadel Pharmaceuticals - Finimize
Will Alkermes plc (8AK) stock benefit from mergersWeekly Investment Recap & Community Supported Trade Ideas - newser.com
Is Alkermes plc (8AK) stock good for wealth creation2025 Investor Takeaways & Safe Entry Momentum Tips - newser.com
Alkermes Plc (ALKS) 財務データ
収益
当期純利益
現金流量
EPS
2.05%
0.35%
大文字化:
|
ボリューム (24 時間):